A Study of YL202 in Patients With Advanced Solid Tumors

This study is testing a new drug called YL202 in people with advanced solid tumors — including certain types of lung cancer, colorectal cancer, cervical cancer, or other cancers that have spread. The drug is a type of targeted therapy designed to attack cancer cells. **You may be eligible if...** - You are 18 or older with a BMI between 18 and 32 - You have been diagnosed with advanced non-squamous lung cancer, colorectal cancer, cervical cancer, or another advanced solid tumor - You have already received 1 or 2 rounds of treatment for your advanced cancer - You have at least one measurable tumor outside the brain - You have tumor tissue available for testing - Your overall health and ability to function is rated as good (ECOG 0 or 1) - You are expected to live at least 3 more months **You may NOT be eligible if...** - You have previously been treated with a drug that targets HER3 - You could not tolerate a type of chemotherapy called topoisomerase I inhibitors before - You have untreated brain metastases or cancer in the lining of the brain - You have uncontrolled heart, lung, or liver problems - You have active hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.